비교리스트

 카트 문의
시장보고서
상품코드
1490331

세계의 분산형 임상시험 시장(2024-2034년)

Decentralised Clinical Trials Market Report 2024-2034
발행일: | 리서치사: Visiongain | 페이지 정보: 영문 321 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 분산형 임상시험 시장 규모는 2034년까지 7.6%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

임상시험의 세계화

임상시험의 세계화는 임상시험 시장을 근본적으로 변화시키고 있습니다. 성장의 원동력은 임상시험 증가이며, 이는 의료를 둘러싼 환경이 크게 변화하고 있음을 보여줍니다. 의약품 개발 일정을 앞당기고, 비용을 절감하며, 다양한 환자 집단에 혁신적인 의약품을 제공해야 할 필요성이 증가하고 있습니다. 제약회사와 생명공학 기업들은 다양한 국가에서 종합적인 임상 데이터를 수집하기 위해 임상시험 수행에 많은 투자를 하고 있습니다. 다양한 집단으로부터 임상 데이터를 수집하는 것은 치료법의 개발과 효과에 큰 영향을 미칩니다. 다양한 인종적, 유전적, 사회경제적 배경을 가진 참가자를 포함시킴으로써 임상시험은 보다 종합적이고 일반화할 수 있는 데이터를 얻을 수 있습니다. 이러한 다양성은 서로 다른 집단이 치료에 어떻게 반응하는지 이해하는 데 도움이 되며, 동질적인 연구 집단에서는 드러나지 않을 수 있는 약물의 효과와 잠재적 부작용의 차이를 밝혀낼 수 있습니다.

세계화는 다양한 지역의 규제 조정을 촉진하는 데 필수적이며, 임상시험 시장에 큰 이점을 가져다줍니다. 규제 당국의 가이드라인과 절차가 전 세계적으로 표준화되면 제약회사는 여러 국가의 복잡한 승인 절차를 한 번에 관리할 수 있게 됩니다. 이러한 협력은 중복 작업을 최소화하고 새로운 치료법의 개발 및 승인을 간소화합니다. 그 결과, 최첨단 치료제 시장 출시 시간이 단축되고, 전 세계 환자들이 새로운 의료 기술에 더 빨리 접근할 수 있게 됩니다. 또한, 일관된 규제 프레임워크는 전 세계 연구자들 간의 협력과 데이터 교환을 촉진하여 임상시험의 전반적인 품질과 효능을 향상시킬 수 있습니다.

세계 분산형 임상시험(Decentralized Clinical Trials) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • COVID-19의 영향 분석
  • Porter의 Five Forces 분석
  • PEST 분석

제4장 분산형 임상시험 시장 분석 : 연구 설계별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 개입적
  • 관찰적
  • 확장 액세스
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제5장 분산형 임상시험 시장 분석 : 적응증별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 종양
  • 심장혈관
  • 면역
  • 호흡기
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제6장 분산형 임상시험 시장 분석 : 최종사용자별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 제약 및 바이오의약품 기업
  • CRO
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제7장 분산형 임상시험 시장 분석 : 컴포넌트별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 모바일 헬스
  • 원격의료
  • 웨어러블 디바이스
  • 웹 기반 기술
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제8장 분산형 임상시험 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추이와 예측

제9장 북미의 분산형 임상시험 시장 분석

제10장 유럽의 분산형 임상시험 시장 분석

제11장 아시아태평양의 분산형 임상시험 시장 분석

제12장 라틴아메리카의 분산형 임상시험 시장 분석

제13장 중동 및 아프리카의 분산형 임상시험 시장 분석

제14장 기업 개요

  • 경쟁 구도
  • 전략적 전망
  • Castor
  • Clario
  • Clinical Ink
  • CLOUDZBYZ, Inc.
  • Dassault Systemes SE(Medidata Solutions, Inc.)
  • Ergomed Group
  • Florence Healthcare, Inc.
  • ICON Plc
  • IQVIA Inc.
  • KORE Wireless Group, Inc.
  • Laboratory Corporation of America Holdings(Covance)
  • Medable Inc.
  • Medrio
  • Oracle Life Sciences
  • Parexel International(MA) Corporation
  • ProPharma Group MIS Limited
  • Science 37
  • Signant Health(CRF Bracket)
  • Syneos Health
  • Thermo Fisher Scientific Inc.(PPD)
  • Veeva Systems

제15장 결론 및 제안

  • Visiongain의 결론
  • 시장 진출기업에 대한 제안
LSH 24.06.14

The global Decentralised Clinical Trials market is estimated to grow at a CAGR of 7.6% by 2034

The Decentralised Clinical Trials Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Globalisation of Clinical Trials

The globalization of clinical trials is fundamentally transforming the clinical trials market. The underline growth is driven by the expanding clinical trials that indicate towards a significant shift in the healthcare landscape. There is a growing need to accelerate drug development timelines, reduce costs, and access of innovative drugs to the diverse patient populations. The pharmaceutical and biotech companies invest heavily into conducting clinical trials to gather comprehensive clinical data across different countries. Gathering clinical data from diverse populations has a profound impact on the development and efficacy of medical treatments. By including participants from various ethnic, genetic, and socio-economic backgrounds, clinical trials can produce more comprehensive and generalizable data. This diversity helps in understanding how different groups respond to treatments, which can uncover variations in drug efficacy and potential side effects that might not be apparent in a homogenous study group.

Globalization is essential in promoting regulatory harmonization across various regions, offering substantial advantages to the clinical trials market. By standardizing regulatory guidelines and procedures internationally, pharmaceutical companies can more easily manage the intricate approval processes in multiple countries at once. This alignment minimizes redundant efforts and simplifies the development and authorization of new therapies. As a result, the time-to-market for cutting-edge treatments is reduced, allowing patients globally to access new medical innovations more quickly. Furthermore, a cohesive regulatory framework fosters increased collaboration and data exchange among researchers worldwide, improving the overall quality and effectiveness of clinical trials.

Concerns Related to Safety and Privacy of Clinical Trials Data

Digital clinical trials (DCTs) heavily rely on digital health technologies and remote data collection methods, making the protection of sensitive patient information a top priority. Concerns regarding data privacy and security can emerge from multiple sources, including unauthorized access to personal health data, breaches of electronic systems, and non-adherence to data protection regulations. Remote monitoring devices, mobile applications, and telemedicine platforms may gather a plethora of sensitive health information, spanning medical history, treatment details, and biometric data. Unauthorized access or misuse of this data could result in privacy breaches, identity theft, and reputational harm for both patients and research organizations.

Data transmission may occur across various platforms, devices, and geographical locations, heightening the risk of data exposure or interception during transit. Moreover, involving third-party vendors like technology providers and cloud service providers further complicates the data security landscape, as these entities may have access to sensitive patient information. Clinical trials often span multiple countries with differing legal jurisdictions, posing challenges in comprehending and adhering to data privacy requirements. Variations in local interpretations of privacy laws in relation to clinical trials contribute to this complexity.

What Questions Should You Ask before Buying a Market Research Report?

How is the decentralised clinical trials Market evolving?

What is driving and restraining the decentralised clinical trials market?

How will each decentralised clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each decentralised clinical trials submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading decentralised clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the decentralised clinical trials projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of decentralised clinical trials projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the decentralised clinical trials market?

Where is the decentralised clinical trials market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Decentralised Clinical Trials Market today, and over the next 10 years:

Our 321-page report provides 141 tables and 168 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Decentralised Clinical Trials Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Decentralised Clinical Trials prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Study Design

Interventional

Observational

Expanded access

Indication

Oncology

Cardiovascular

Immunology

Respiratory

Others

Component

Mobile Healthcare

Telemedicine

Wearable Devices

Web-based Technology

Others

End-users

Pharmaceutical and Biopharmaceutical Companies

CROs

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 27 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Poland

Belgium

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Decentralised Clinical Trials Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Castor

Clario

Clinical Ink

Cloudbyz

Dassault SystemesSE (Medidata Solutions, Inc.)

Ergomed Group

Florence Healthcare, Inc.

ICON Plc

IQVIA Inc.

KORE Wireless Group, Inc.

Laboratory Corporation of America Holdings (Covance)

Medable Inc.

Medrio

Oracle Life Sciences

Parexel International (MA) Corporation

ProPharma Group MIS Limited

Science 37

Signant Health (CRF Bracket)

Syneos Health

Thermo Fisher Scientific Inc. (PPD)

Veeva Systems

Overall world revenue for Decentralised Clinical Trials Market, 2024 to 2034 in terms of value the market will surpass US$9,200.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Decentralised Clinical Trials Market, 2024 to 2034 report help you?

In summary, our 320+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Decentralised Clinical Trials Market, 2024 to 2034, with forecasts for study design, indication, end-users and component, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Decentralised Clinical Trials Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Decentralised Clinical Trials Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Decentralised Clinical Trials Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Decentralised Clinical Trials Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Advancements in Digital Health Technologies
      • 3.2.1.2 Globalisation of Clinical Trials
      • 3.2.1.3 Increasing Demand for Real-World Evidence
      • 3.2.1.4 Regulatory Support and Guidance
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Data Privacy and Security Concerns
      • 3.2.2.2 Technological Limitations and Standardization
      • 3.2.2.3 Infrastructure and Resource Constraints
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Acceleration of Drug Development and Innovation
      • 3.2.3.2 Expansion of Clinical Trial Activities into Emerging Markets
      • 3.2.3.3 Increasing Partnerships and Collaborations Between Pharmaceutical Companies
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Decentralised Clinical Trials Market Analysis by Study Design

  • 4.1 Key Findings
  • 4.2 Study Design Segment: Market Attractiveness Index
  • 4.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 4.4 Interventional
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Observational
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Expanded Access
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Decentralised Clinical Trials Market Analysis by Indication

  • 5.1 Key Findings
  • 5.2 Study Design Segment: Market Attractiveness Index
  • 5.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 5.4 Oncology
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Cardiovascular
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Immunology
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Respiratory
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Others
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)

6 Decentralised Clinical Trials Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-user Segment: Market Attractiveness Index
  • 6.3 Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 6.4 Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Clinical Research Organisations (CROs)
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Others
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Decentralised Clinical Trials Market Analysis by Component

  • 7.1 Key Findings
  • 7.2 Component Segment: Market Attractiveness Index
  • 7.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 7.4 Mobile Healthcare
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Telemedicine
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Wearable Devices
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Web-based Technology
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)
  • 7.8 Others
    • 7.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.8.2 Market Share by Region, 2024 & 2034 (%)

8 Decentralised Clinical Trials Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Decentralised Clinical Trials Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Decentralised Clinical Trials Market Attractiveness Index
  • 9.3 North America Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 9.5 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 9.6 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 9.7 North America Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 9.8 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 9.9 U.S. Decentralised Clinical Trials Market Analysis
  • 9.10 Canada Decentralised Clinical Trials Market Analysis

10 Europe Decentralised Clinical Trials Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Decentralised Clinical Trials Market Attractiveness Index
  • 10.3 Europe Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 10.5 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 10.6 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 10.7 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 10.8 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 10.9 Germany Decentralised Clinical Trials Market Analysis
  • 10.10 France Decentralised Clinical Trials Market Analysis
  • 10.11 UK Decentralised Clinical Trials Market Analysis
  • 10.12 Italy Decentralised Clinical Trials Market Analysis
  • 10.13 Spain Decentralised Clinical Trials Market Analysis
  • 10.14 Russia Decentralised Clinical Trials Market Analysis
  • 10.15 Poland Decentralised Clinical Trials Market Analysis
  • 10.16 Belgium Decentralised Clinical Trials Market Analysis
  • 10.17 Rest of Europe Decentralised Clinical Trials Market Analysis

11 Asia Pacific Decentralised Clinical Trials Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Decentralised Clinical Trials Market Attractiveness Index
  • 11.3 Asia Pacific Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 11.6 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 11.7 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 11.8 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 11.9 Japan Decentralised Clinical Trials Market Analysis
  • 11.10 China Decentralised Clinical Trials Market Analysis
  • 11.11 India Decentralised Clinical Trials Market Analysis
  • 11.12 Australia Decentralised Clinical Trials Market Analysis
  • 11.13 South Korea Decentralised Clinical Trials Market Analysis
  • 11.14 Singapore Decentralised Clinical Trials Market Analysis
  • 11.15 Taiwan Decentralised Clinical Trials Market Analysis
  • 11.16 Rest of Asia Pacific Decentralised Clinical Trials Market Analysis

12 Latin America Decentralised Clinical Trials Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Decentralised Clinical Trials Market Attractiveness Index
  • 12.3 Latin America Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 12.5 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 12.6 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 12.7 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 12.8 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 12.9 Brazil Decentralised Clinical Trials Market Analysis
  • 12.10 Mexico Decentralised Clinical Trials Market Analysis
  • 12.11 Argentina Decentralised Clinical Trials Market Analysis
  • 12.12 Colombia Decentralised Clinical Trials Market Analysis
  • 12.13 Rest of Latin America Decentralised Clinical Trials Market Analysis

13 MEA Decentralised Clinical Trials Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Decentralised Clinical Trials Market Attractiveness Index
  • 13.3 MEA Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 13.5 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 13.6 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 13.7 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 13.8 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 13.9 GCC Decentralised Clinical Trials Market Analysis
  • 13.10 South Africa Decentralised Clinical Trials Market Analysis
  • 13.11 Rest of MEA Decentralised Clinical Trials Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2023
  • 14.2 Strategic Outlook
  • 14.3 Castor
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Product Benchmarking
    • 14.3.4 Strategic Outlook
  • 14.4 Clario
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Product Benchmarking
    • 14.4.4 Strategic Outlook
  • 14.5 Clinical Ink
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
    • 14.5.4 Strategic Outlook
  • 14.6 CLOUDZBYZ, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Product Benchmarking
    • 14.6.4 Strategic Outlook
  • 14.7 Dassault Systemes SE (Medidata Solutions, Inc.)
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2017-2023
      • 14.7.3.2 R&D, 2017-2023
      • 14.7.3.3 Regional Market Shares, 2023
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Ergomed Group
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
    • 14.8.4 Strategic Outlook
  • 14.9 Florence Healthcare, Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 ICON Plc
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2023
      • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 IQVIA Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2023
      • 14.11.3.2 Regional Market Shares, 2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 KORE Wireless Group, Inc.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2019-2023
      • 14.12.3.2 Regional Market Shares, 2023
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Laboratory Corporation of America Holdings (Covance)
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2023
      • 14.13.3.2 Regional Market Shares, 2022
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Medable Inc.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Medrio
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Product Benchmarking
  • 14.16 Oracle Life Sciences
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2023
      • 14.16.3.2 Regional Market Shares, 2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Parexel International (MA) Corporation
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
    • 14.17.4 Strategic Outlook
  • 14.18 ProPharma Group MIS Limited
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Product Benchmarking
    • 14.18.4 Strategic Outlook
  • 14.19 Science 37
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Product Benchmarking
    • 14.19.4 Strategic Outlook
  • 14.20 Signant Health (CRF Bracket)
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Product Benchmarking
    • 14.20.4 Strategic Outlook
  • 14.21 Syneos Health
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2017-2022
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook
  • 14.22 Thermo Fisher Scientific Inc. (PPD)
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Financial Analysis
      • 14.22.3.1 Net Revenue, 2017-2023
      • 14.22.3.2 R&D, 2017-2023
      • 14.22.3.3 Regional Market Shares, 2023
    • 14.22.4 Product Benchmarking
    • 14.22.5 Strategic Outlook
  • 14.23 Veeva Systems
    • 14.23.1 Company Snapshot
    • 14.23.2 Company Overview
    • 14.23.3 Financial Analysis
      • 14.23.3.1 Net Revenue, 2017-2023
      • 14.23.3.2 R&D, 2017-2023
      • 14.23.3.3 Regional Market Shares, 2023
    • 14.23.4 Product Benchmarking
    • 14.23.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제